Lonza expands partnership with US pharmaceutical customer

1. Jul 2026

(AWP Alliance News) - Lonza Group AG on Wednesday said it was expanding a collaboration with a US biopharmaceutical firm.

The Basel, Switzerland-based contract development and manufacturing company noted that the tie-up spans several contracts across process intensification and drug manufacturing, with " the potential to deliver a multi-billion cumulative CHF value".

Exact financial details of the partnership were not disclosed, nor was the name of the customer, but Lonza said it had an existing relationship with the company in question.

"The expansion adds two biologics programs to be produced commercially, with the option for two more, and further strengthens an established multi-year relationship, including long-term commitments across a broad portfolio of multiple biologics programs. This evolving portfolio of innovative programs supports flexibility in demand and development risk, with the ability to scale programs over time, including the transition into commercial manufacturing," Lonza said.

"Lonza will leverage its broad technology portfolio for mammalian antibodies, including advanced process intensification such as N-1 perfusion. In addition, Lonza supports the company with manufacturing process optimizations that will materially reduce cycle times across selected programs," it continued.

The company will provide services from its US sites, supported by its European capabilities.

Gordon Bates, head of Integrated Biologics at Lonza, commented: "This strategic collaboration demonstrates Lonza's role as a trusted manufacturing partner for large biopharmaceutical companies. By combining cutting-edge science, smart technology and lean manufacturing in our global network, Lonza enables customers to advance complex portfolios, combining speed and flexibility with high quality and reliability."

Lonza shares closed 1.2% higher at CHF545.80 on Tuesday in Zurich.

By Holly Munks, Alliance News reporter

Comments and questions to newsroom [at] alliancenews.com